Search Results | Clinicalinfo

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2441 – 2460 of 3236

Cost Considerations and Antiretroviral Therapy

https://clinicalinfo.hiv.gov/node/9196

Management of Medication Toxicity or Intolerance

https://clinicalinfo.hiv.gov/node/9197

Hematologic Effects

https://clinicalinfo.hiv.gov/node/9198

Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)

https://clinicalinfo.hiv.gov/node/9199

https://clinicalinfo.hiv.gov/node/9200

https://clinicalinfo.hiv.gov/node/9201

https://clinicalinfo.hiv.gov/node/9202

Entry and Fusion Inhibitors

https://clinicalinfo.hiv.gov/node/9203

Management of Children Receiving Antiretroviral Therapy

https://clinicalinfo.hiv.gov/node/9204

Hepatitis B Virus Infection

https://clinicalinfo.hiv.gov/node/9205

Care of Infants With Perinatal Exposure to HIV

https://clinicalinfo.hiv.gov/node/9209

Antiretroviral Management of Infants With In Utero, Intrapartum, or Breastfeeding Exposure to HIV

https://clinicalinfo.hiv.gov/node/9210

Fosamprenavir (Lexiva, FPV)

https://clinicalinfo.hiv.gov/node/9211

https://clinicalinfo.hiv.gov/node/9212

https://clinicalinfo.hiv.gov/node/9213

Suboptimal CD4 Cell Recovery Despite Viral Suppression

https://clinicalinfo.hiv.gov/node/9215

Hepatitis C Virus/HIV Coinfection

https://clinicalinfo.hiv.gov/node/9216

Raltegravir (Isentress, Isentress HD, RAL)

https://clinicalinfo.hiv.gov/node/9217

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors

https://clinicalinfo.hiv.gov/node/9218

Drug-Drug Interactions

https://clinicalinfo.hiv.gov/node/9219